Statin Prescribing & Lipid Modification Guideline
for the Prevention of Cardiovascular Disease

Disclaimer

This guideline is registered at North Central London (NCL) Joint Formulary Committee (JFC) and is intended solely for use by healthcare professionals to aid the treatment of patients within NCL. However, clinical guidelines are guidelines only, their interpretation and application remain the responsibility of the individual clinician. If in doubt, contact a senior colleague or expert. Clinicians are advised to refer to the manufacturer’s current prescribing information before treating individual patients.

The authors and NCL JFC accept no liability for use of this information beyond its intended use.

While we have tried to compile accurate information in this guideline, and to keep it updated in a timely manner, we cannot guarantee that it is fully complete and correct at all times. If you identify information within this guideline that is inaccurate, please report this to the admin.ncl-mon@nhs.net. If a patient is harmed as a consequence of following this guideline, please complete a local incident report and inform admin.ncl-mon@nhs.net.

This guideline is not be to used or reproduced for commercial or marketing purposes.
## Document control

<table>
<thead>
<tr>
<th>Date</th>
<th>Version</th>
<th>Amendments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dec 2015</td>
<td>1</td>
<td>New Guideline</td>
</tr>
<tr>
<td>Jan 2020</td>
<td>2</td>
<td>Change from QRISK2 to QRISK for CV risk stratification</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Removal of “last line option” for rosuvastatin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Linking NCL JFC documents on omega fatty acids and management of hypertriglyceridemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Addition of PCSK9i paragraph</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Update of content in appendix 1 and appendix 2</td>
</tr>
</tbody>
</table>

## Document management

<table>
<thead>
<tr>
<th>Groups / Individuals who have overseen the development of this guidance:</th>
<th>Shalina Dhalla, RFL Senior Cardiology Pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Groups which were consulted and have given approval:</td>
<td>Dr Catherine Lunken, UCLH Lipid &amp; Endocrinology Specialist</td>
</tr>
<tr>
<td></td>
<td>Dr Devaki Nair, RFH Clinical Lead for Lipids &amp; CVD Prevention</td>
</tr>
<tr>
<td></td>
<td>NCL JFC Formulary Pharmacists (UCLH, RFH, WH, MEH, NMUH, GOSH, RNOH, BEH &amp; C&amp;I MH Trusts)</td>
</tr>
<tr>
<td></td>
<td>NCL JFC CCG Representatives (Camden, Islington, Barnet, Haringey, Enfield)</td>
</tr>
<tr>
<td>File name:</td>
<td>Statin Prescribing &amp; Lipid Modification Guideline</td>
</tr>
<tr>
<td>Version number:</td>
<td>2</td>
</tr>
<tr>
<td>Disseminated to:</td>
<td>NCL JFC Formulary Pharmacists and CCG Leads</td>
</tr>
<tr>
<td>Equality impact assessment:</td>
<td>Low</td>
</tr>
<tr>
<td>NCL Joint Formulary Committee Approval date:</td>
<td>January 2020</td>
</tr>
<tr>
<td>Review date:</td>
<td>January 2023</td>
</tr>
</tbody>
</table>
Contents

1. Target audience ........................................................................................................................................ 4
2. Purpose .................................................................................................................................................. 4
3. Introduction ............................................................................................................................................ 4
4. Cardiovascular Disease (CVD) Risk Assessment .................................................................................. 4
5. Lifestyle Advice for Primary & Secondary Prevention of CVD ............................................................. 4
6. Statin Treatment Guidance .................................................................................................................... 5
   6.1. Statins in Patients with Renal Impairment ....................................................................................... 5
   6.2. Statins in Patients with Diabetes ..................................................................................................... 5
   6.3. Statins in Pregnancy & Breastfeeding .............................................................................................. 5
   6.4. Relative Statin Intensities ................................................................................................................ 5
7. Monitoring .............................................................................................................................................. 6
   7.1. Advice and monitoring for adverse effects ...................................................................................... 6
   7.2 Muscle-Related Adverse Effects ....................................................................................................... 7
   7.3 Intolerance of statins .......................................................................................................................... 7
   7.4 Liver Function Tests (LFTs) ............................................................................................................... 7
8. Lipid-Lowering Therapies ...................................................................................................................... 8
   8.1. Ezetimibe ........................................................................................................................................ 8
   8.2. PCSK9 inhibitors (alirocumab and evolocumab) ............................................................................. 8
   8.3. Therapies that are NOT Recommended ........................................................................................ 8
9. Lipid Clinic Contact Details .................................................................................................................. 9
10. References ............................................................................................................................................ 9
Appendix 1: Statin Guidelines .................................................................................................................... 11
Appendix 2: Statin Interactions Table ....................................................................................................... 12
1. **Target audience**
Hospital clinicians, GPs, non-medical prescribers, specialist nurses and pharmacists.

2. **Purpose**
To provide guidance on appropriate prescribing of statins in different adult patient groups and use of other lipid modifying therapies e.g. ezetimibe.

3. **Introduction**
NICE issued updated guidance on lipid modification (CG181) in September 2016. This NCL JFC guidance reflects updated information based on NICE guidance, current pricing of statins and a search of interactions and contraindications.

4. **Cardiovascular Disease (CVD) Risk Assessment**
Be aware that all CVD risk assessment tools can provide only an approximate value for CVD risk. Interpretation of CVD risk scores should always reflect informed clinical judgement.

Use the QRISK risk assessment tool to assess CVD risk for primary prevention – available via http://www.qrisk.org/ or automatically via GP patient record systems.

The following treatment groups are at higher baseline CVD risk, and therefore a further risk assessment is not required:

- patients ≥85 years old
- patients with type 1 diabetes (see section 7.2.1)
- eGFR <60ml/min/1.73m² and/or albuminuria
- pre-existing CVD (secondary prevention)
- familial hypercholesterolaemia or other inherited disorders of lipid metabolism

Be aware that standard CVD risk scores will underestimate risk in people who have additional risk because of underlying medical conditions or treatments. These groups include:

- people treated for HIV
- people with serious mental health problems
- people taking medicines that can cause dyslipidaemia such as antipsychotic medication, corticosteroids or immunosuppressant drugs
- people with autoimmune disorders such as systemic lupus erythematosus, and other systemic inflammatory disorders.

Use clinical judgement when using risk scores to inform treatment decisions in these patient groups.

Also recognise that CVD risk will be underestimated in people who are already taking antihypertensive or lipid modification therapy, or who have recently stopped smoking. Use clinical judgement to decide on further treatment of risk factors in people who are below the CVD risk threshold for treatment.

Refer to NICE CG181 (http://www.nice.org.uk/guidance/cg181/) for further information on identifying patients and assessing CVD risk.

5. **Lifestyle Advice for Primary & Secondary Prevention of CVD**
Advise all patients to make lifestyle modifications to reduce their CVD risk including cardio-protective diet, physical activity, weight management, reduced alcohol consumption and smoking cessation.
6. Statin Treatment Guidance

See Appendix 1 for flow chart and guidance on statin treatment in primary and secondary prevention. Common interactions of statins and management advice are listed in Appendix 2; please note that this list is not exhaustive and users should also refer to product Summary of Product Characteristics (SPCs) or ask a pharmacist for up-to-date advice.

6.1. Statins in Patients with Renal Impairment

For primary and secondary prevention of CVD in patients with chronic kidney disease (CKD) offer atorvastatin 20mg daily. The dose can be increased if >40% reduction in non-HDL cholesterol is not achieved and eGFR is ≥30ml/min/1.73m². Agree the use of higher doses with a renal specialist if eGFR is <30ml/min/1.73m².

6.2. Statins in Patients with Diabetes

6.2.1. Type 1 Diabetes

Consider statin therapy in all patients with type 1 diabetes as this patient group has a higher baseline CVD risk. Offer atorvastatin 20mg for primary prevention of CVD to adults with type 1 diabetes who have one or more of the following risk factors:

- Age >40 years
- Had diabetes for >10 years
- Established nephropathy
- Other CVD risk factors

6.2.2. Type 2 Diabetes

Offer atorvastatin 20mg for primary prevention of CVD to all patients with type 2 diabetes and with an estimated 10-year CVD risk ≥10%.

6.3. Statins in Pregnancy & Breastfeeding

Statins are contraindicated in pregnancy due to reports of congenital anomalies and effects on foetal development. Advise women of childbearing potential of the potential teratogenic risk of statins and to stop taking them if pregnancy is a possibility. Statins should ideally be discontinued 3 months before women attempt to conceive.

Statins are contraindicated in women who are breastfeeding.

6.4. Relative Statin Intensities

<table>
<thead>
<tr>
<th>Statin Intensity</th>
<th>Daily Dose (reduction in LDL cholesterol)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>High-Intensity</td>
<td></td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>80mg (55%)</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>40mg (49%)</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>20mg (43%)</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>80mg (42%) see note below</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>40mg (53%)</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>20mg (48%)</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>10mg (43%)</td>
</tr>
</tbody>
</table>
Atorvastatin is the first line statin for primary and secondary prevention of CVD.

Fluvastatin is not included in this table as it is not recommended or included on the NCL JFC formulary.

There is a particularly high risk of myopathy associated with high dose (80mg) simvastatin, and it is therefore not recommended for patients newly initiated on a statin. Please see further details on the MHRA Drug Safety Update see MHRA Drug Safety Update at [https://www.gov.uk/drug-safety-update/simvastatin-increased-risk-of-myopathy-at-high-dose-80-mg](https://www.gov.uk/drug-safety-update/simvastatin-increased-risk-of-myopathy-at-high-dose-80-mg)

### 7. Monitoring

Prior to initiating lipid modification therapy a baseline full lipid profile should be measured (this does not need to be fasting) if these have not been done in the last 3 months. This should include total cholesterol (TC), HDL cholesterol, non-HDL cholesterol, LDL cholesterol (LDL-C) and triglyceride levels. Urea and electrolytes, Liver Function Tests (LFTs), HbA1c and thyroid stimulating hormone (TSH) should also be taken. Secondary causes of dyslipidaemia should be excluded. The following groups should be referred to a lipid clinic (see contact details in section 10):

- Patients with baseline TC >7.5 mmol/L and family history of premature CHD
- Any patient with baseline TC >9.0mmol/L or non-HDL cholesterol >7.5mmol/L
- Patients with a triglyceride level >10mmol/L after two measurements (see NICE CG181 for further details). Please consult NCL Guidance for the management of hypertriglyceridaemia
- Urgently refer patients with triglyceride level >20 mmol/L that is not related to excess alcohol or poor glycaemic control. Please consult JFC NCL Guidance for the management of hypertriglyceridaemia
- Patients at high-risk of CVD who are intolerant to 3 different statins

Lipid profiles should be measured at baseline and 3 months. Consider measuring every 12 months thereafter (or after 6 months if the dose/statin changes). The results should be used to inform annual medication reviews where adherence, lifestyle modifications and CVD risk factors can be discussed. Aim for ≥ 40% reduction in non-HDL cholesterol. If a 40% reduction in non-HDL cholesterol is achieved, there is no need to continue repeating the full lipid profile in primary prevention.

LFTs should be measured at baseline, 3 months and 12 months. Statins do not require further routine LFT monitoring if stable at 12 months unless clinically indicated.

### 7.1. Advice and monitoring for adverse effects

The most common adverse effects associated with statins include: muscle related adverse effects (see Section 7.2 below), headaches, gastrointestinal disturbances, nasopharyngitis and sleep disturbances. If significant; consider changing time of dose, reducing the dose or switching to an alternative agent.

<table>
<thead>
<tr>
<th>Medium-Intensity</th>
<th>Atorvastatin 10mg (37%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Simvastatin 40mg (37%)</td>
</tr>
<tr>
<td></td>
<td>Simvastatin 20mg (32%)</td>
</tr>
<tr>
<td></td>
<td>Rosuvastatin 5mg (38%)</td>
</tr>
<tr>
<td>Low-Intensity</td>
<td>Pravastatin 40mg (29%)</td>
</tr>
<tr>
<td></td>
<td>Pravastatin 20mg (24%)</td>
</tr>
<tr>
<td></td>
<td>Pravastatin 10mg (20%)</td>
</tr>
<tr>
<td></td>
<td>Simvastatin 10mg (27%)</td>
</tr>
</tbody>
</table>
Advise people who are being treated with a statin that other drugs, some foods (for example, grapefruit juice) and some supplements may interfere with statins and to always consult the patient information leaflet, a pharmacist or prescriber for advice when starting other drugs or thinking about taking supplements.

Remind the person to restart the statin if they stopped taking it because of drug interactions or to treat intercurrent illnesses.

Advise people who are being treated with a statin to seek medical advice if they develop muscle symptoms such as pain, tenderness or weakness (see section 7.2 below).

### 7.2. Muscle-Related Adverse Effects

Muscle-related problems are the most frequently reported side effect of statins. All statins have a dose-dependent increased risk of myopathy. Interactions with other medications may also increase the risk of myopathy (see Appendix 2).

Patients should be counselled to report any unusual muscle pain, tenderness or weakness. Creatine kinase (CK) levels should be measured in patients reporting these symptoms, and appropriate action taken as below.

- Where CK levels are (in the absence of strenuous exercise) >5x the upper limit of normal, stop/avoid statins. If symptoms resolve and CK levels return to normal, then re-introduction of the statin or of an alternative statin may be considered at the lowest dose and with close monitoring.
- Where CK levels are (in the absence of strenuous exercise) raised but <5x the upper limit of normal, consider a reduced statin dose.
- Where patients reporting muscle pain/weakness have previously tolerated statin therapy for >3 months, explore other possible causes of muscle pain/weakness.

There is a particularly high risk of myopathy associated with high dose (80mg) simvastatin, and it is therefore not recommended for patients newly initiated on a statin. For patients already established on simvastatin 80mg, continue only if the patient has not experienced muscle-related side effects.

### 7.3. Intolerance of statins

If a patient is not able to tolerate a high-intensity statin aim to treat with the maximum tolerated dose.

Tell the person that any statin at any dose reduces CVD risk. If someone reports adverse effects when taking high-intensity statin discuss the following possible strategies with them:

- stopping the statin and trying again when the symptoms have resolved to check if the symptoms are related to the statin
- reducing the dose within the same intensity group
- changing the statin to a lower intensity group.

Patients at high risk of CVD who are intolerant to 3 different statin should be referred to a lipid clinic (see contact details in section 9).

### 7.4. Liver Function Tests (LFTs)

Measure LFTs at baseline, 3 months and 12 months. Thereafter only test if clinically indicated. Consider stopping/reducing statins when LFTs are raised >3x the upper limit of normal.
8. Lipid-Lowering Therapies

8.1. Ezetimibe

Ezetimibe is licensed and recommended by NICE (TA385) for patients with primary hypercholesterolaemia where a statin is contraindicated, not tolerated (consider referral to lipid specialist) or as an adjunct where high intensity statins have failed to sufficiently reduce cholesterol levels.

8.2. PCSK9 inhibitors (alirocumab and evolocumab)

Alirocumab and evolocumab are monoclonal antibodies that target proprotein convertase subtilisin/kexin type 9 (PCSK9). They stop low-density lipoprotein receptors in the liver from degrading, helping to lower levels of LDL-C in the blood. Alirocumab and evolocumab are licensed and recommended by NICE (TA393 and TA394 respectively) for patients with primary hypercholesterolaemia (heterozygous-familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

- in combination with a statin, or a statin plus other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,
- alone or in combination with other lipid-lowering therapies in patients who cannot tolerate or cannot be given statins.

If the patient meets the NICE criteria below for a PCSK9i, a referral should be made to the lipid clinic for further monitoring and prescribing. PCSK9i can only be prescribed in secondary care.

<table>
<thead>
<tr>
<th>Without CVD</th>
<th>With CVD</th>
</tr>
</thead>
<tbody>
<tr>
<td>High risk of CVD</td>
<td>Very high risk of CVD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Primary non-familial hypercholesterolaemia or mixed dyslipidaemia</th>
<th>Not recommended at any LDL-C concentration</th>
<th>Recommended only if LDL-C concentration is persistently above 4.0 mmol/litre</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary heterozygous-familial hypercholesterolaemia</td>
<td>Recommended only if LDL-C concentration is persistently above 5.0 mmol/litre</td>
<td>Recommended only if LDL-C concentration is persistently above 3.5 mmol/litre</td>
</tr>
</tbody>
</table>

1. High risk of CVD is defined as a history of any of the following: acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation); coronary or other arterial revascularisation procedures; coronary heart disease; ischaemic stroke; peripheral arterial disease.

2. Very high risk of CVD is defined as recurrent cardiovascular events or cardiovascular events in more than 1 vascular bed (that is, polyvascular disease).

Abbreviations: CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.

8.3. Therapies that are NOT Recommended

The following therapies should NOT be prescribed due to limited evidence of benefit.

- Fibrates (unless advised by a lipid specialist)
- Bile acid sequestrants (unless advised by a lipid specialist)
- Nicotinic acid (no longer available in the UK)
- Omega-3 fatty acid compounds (please refer to NCL JFC Guidance for the review of omega-3 fatty acids (including Omacor®))
- Plant stanols and sterols
- Co-enzyme Q10 or vitamin D to increase adherence to statin

For patients established on these therapies, consider stopping and optimising statin therapy where appropriate. If patients wish to purchase omega-3 fatty acids, plant stanols/sterols, co-enzyme Q10 or vitamin D over the counter, there is no evidence of harm in this.

9. Lipid Clinic Contact Details

<table>
<thead>
<tr>
<th>Royal Free London NHS Foundation Trust</th>
<th>UCLH NHS Foundation Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Devaki Nair</td>
<td>Dr Catherine Lunken</td>
</tr>
<tr>
<td>Clinical Lead for Lipids &amp; CVD Prevention</td>
<td>Department of Diabetes &amp; Endocrinology</td>
</tr>
<tr>
<td><a href="mailto:Devaki.nair@nhs.net">Devaki.nair@nhs.net</a></td>
<td>250 Euston Road, London NW1 2PG</td>
</tr>
<tr>
<td>Tel: 020 7472 6694 Ext 33489</td>
<td><a href="mailto:Catherine.lunken@nhs.net">Catherine.lunken@nhs.net</a></td>
</tr>
<tr>
<td>Clinical Nurse Specialist Tel: 020 317 7723</td>
<td></td>
</tr>
</tbody>
</table>

10. References

14) Liverpool HIV drugs interaction checker. Accessed online on 27/08/19 via https://www.hiv-druginteractions.org/checker
15) NCL Right Test Right Time Pathology Guidance – Updated Phase 1 & 2 July 2019
Appendix 1: Statin Guidelines

**Primary Prevention**

- CVD risk ≥10% over next 10 years
- Age ≥85 years
- eGFR <60ml/min/1.73m2 and/or albuminuria
- Adults with type 1 or type 2 diabetes (see guidance in Section 6.2)

Give lifestyle advice. Ensure regular review of CV risk and lipid levels.

Identify and address all modifiable risk factors: smoking, diet, alcohol intake, BP control and physical activity.

In secondary prevention, do not delay statin treatment to manage modifiable risk factors. Consider patient preference, concurrent medication, co-morbidities (see guidance in Section 6) and life expectancy before initiating statin.

**Secondary Prevention**

All patients with CVD or atherosclerotic vascular disease – ischaemic heart disease, stroke, TIA, peripheral artery disease, ACS

Initiate ATORVASTATIN 80mg daily

Initiate Atorvastatin 20mg daily in renal impairment, elderly patients with low muscle mass, and in those who have history of muscle disorders. Lower doses may be required with interacting drugs, please refer to Appendix 2: Statin Interactions Table for dose recommendations.

If failed to reach target lipid levels assess adherence, patient preference and co-morbidities and consider

1. increase to ATORVASTATIN 40mg or 80mg daily (if not already optimised) OR
2. EZETIMIBE 10mg daily as adjunct (see guidance section 8.1).
3. If patient eligible for a PCSK9i, refer to lipid clinic

**Familial Hypercholesterolaemia**

or other inherited disorders of lipid metabolism.

Refer to lipid clinic (see Section 9)

If intolerant (exclude other potential causes including drug interactions) either:

1. STOP & RETRIAL when symptoms are resolved to establish if symptoms are statin-related
2. Lower dose ATORVASTATIN, titrated up as tolerated
3. ROSUVASTATIN 5mg and titrate up to 40mg as tolerated (check for interactions)
4. SIMVASTATIN 20mg and titrate up to 40mg as tolerated (check for interactions)
5. PRAVASTATIN 20mg and titrate up as tolerated - NB lower intensity statin

Repeat lipid profile after 3 months. Aim for >40% reduction in non-HDL cholesterol (>50% reduction for patients with familial hypercholesterolaemia)

Repeat lipid profile after 3 months. Aim for >40% reduction in non-HDL cholesterol is an indicator of treatment effect. If this is not achieved consider adherence, tolerance and whether a higher statin dose is appropriate.
### Appendix 2: Statin Interactions Table

<table>
<thead>
<tr>
<th>Interacting Drug</th>
<th>Atorvastatin Advice</th>
<th>Simvastatin Advice</th>
<th>Rosuvastatin advice</th>
<th>Pravastatin Advice</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Macrolides</strong> - clarithromycin, erythromycin, telithromycin</td>
<td>Avoid if possible (i.e. stop atorvastatin for duration if short course). If required, counsel patient to report any symptoms of myopathy. Monitor lipid levels to ensure lowest necessary dose of atorvastatin.</td>
<td>Contraindicated with simvastatin</td>
<td>Macrolides: Use with caution. Counsel patient to report any symptoms of myopathy.</td>
<td>Nil significant interaction reported – dose as normal</td>
</tr>
<tr>
<td><strong>Azoles</strong> – itraconazole, ketoconazole, posaconazole</td>
<td></td>
<td></td>
<td>Azoles: Nil significant interaction reported – dose as normal</td>
<td></td>
</tr>
<tr>
<td>Amiodarone, verapamil, diltiazem, amlodipine</td>
<td>May increase statin levels – counsel patient to report any symptoms of myopathy. Monitor lipid levels to ensure lowest necessary dose of atorvastatin is used.</td>
<td>Do not exceed simvastatin 20mg daily</td>
<td>Nil significant interaction reported – dose as normal</td>
<td>Nil significant interaction reported – dose as normal</td>
</tr>
<tr>
<td><strong>HIV Protease Inhibitors</strong> e.g. tipranavir, ritonavir, nelfinavir, lopinavir</td>
<td>Initiate atorvastatin 10mg daily. If target lipid levels not achieved, consider atorvastatin 20mg and seek advice from pharmacist/HIV team/lipid team. Counsel patient to report any symptoms of myopathy.</td>
<td>Contraindicated with simvastatin</td>
<td>Atorvastatin in the preferred option. If high risk patient or target lipid levels not achieved with atorvastatin, start with the lowest possible dose of rosuvastatin and seek advice from pharmacist/HIV team/lipid team.</td>
<td>Atorvastatin is the preferred option. If pravastatin required due to intolerance to other statins, initiate pravastatin 20mg daily and if tolerated titrate up to 40mg daily with caution. Counsel patient to report any symptoms of myopathy.</td>
</tr>
<tr>
<td>Ciclosporin, gemfibrozil, danazol, nefazodone</td>
<td>Do not exceed atorvastatin 10mg daily</td>
<td>Contraindicated with simvastatin</td>
<td>Contraindicated with rosuvastatin</td>
<td>Ciclosporin: Initiate pravastatin 20mg daily and if tolerated titrate up to 40mg daily with caution. Gemfibrozil: Avoid combined use. If required, monitor lipid levels to ensure lowest necessary dose of pravastatin is used. Counsel patient to report any symptoms of myopathy.</td>
</tr>
<tr>
<td>Other fibrates (for gemfibrozil see above)</td>
<td>Counsel patient to report any symptoms of myopathy. Monitor lipid levels to ensure lowest necessary dose of atorvastatin is used.</td>
<td>Do not exceed simvastatin 10mg daily (except fenofibrate - no dose alteration required, but monitor for adverse effects)</td>
<td>Counsel patient to report any symptoms of myopathy. Monitor lipid levels to ensure lowest necessary dose of rosuvastatin is used. Avoid rosuvastatin 40mg daily.</td>
<td>Counsel patient to report any symptoms of myopathy. Monitor lipid levels to ensure lowest necessary dose of pravastatin is used.</td>
</tr>
<tr>
<td><strong>Fusidic Acid (systemic)</strong></td>
<td>Avoid if possible (i.e. if short course stop statin until 7 days after course is finished). If required, counsel patient to report any symptoms of myopathy. Monitor lipid levels to ensure lowest necessary dose of statin is used.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ezetimibe</strong></td>
<td>Possible additive risk of myopathy. Counsel patient to report any signs of myopathy.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Warfarin/Coumarins</strong></td>
<td>Monitor INR on initiation and with dose changes.</td>
<td></td>
<td></td>
<td>Nil significant interaction reported</td>
</tr>
<tr>
<td><strong>Grapefruit Juice</strong></td>
<td>Avoid large quantities (&gt;1.2L a day), the occasional glass is thought to be safe</td>
<td>Avoid while taking simvastatin.</td>
<td>Information is lacking but no interaction would be expected</td>
<td></td>
</tr>
</tbody>
</table>